DXCM — DexCom, Inc.

Post-Q2 sentiment is bullish: revenue grew 13.1% YoY to $1.31B, non-GAAP EPS of $0.70 beat estimates by roughly 15%, and management raised 2026 revenue guidance to $5.18-5.25B with operating margin guided to 23.5-24%. Analysts raised targets after the print (Citi to $105, Argus to $96, Piper Sandler/TD Cowen to $95), and DXCM recovered quickly from the Insulet-driven med-tech selloff.

Revenue growth inflected from ~2% YoY in Q3 2024 and 7.6% in Q4 2024 to 12.5-15.2% through 2025, spiked to 21.6% in Q3 2025, then stabilized around 13.1-15.0% over the last three quarters. That is acceleration followed by settling into a mid-teens growth range, not deceleration. Operating margins expanded from low-teens in early 2025 to 18.4% in Q2 2025, 20.1% in Q3 2025, 25.6% in Q4 2025, and 24.3% in Q2 2026. Quarterly GAAP EPS progressed from $0.27 in Q1 2025 to $0.51-0.70 over the past four quarters. The soft spot is quarterly operating cash flow of $269M in Q2 2026 versus $303M a year earlier, but TTM FCF is still roughly $1.41B and the accruals ratio is a healthy -0.31%, suggesting earnings quality is solid.

As of 2026-08-27, DXCM trades at 34.5x trailing EPS, about 33.5x forward EPS using the $2.668 consensus estimate, and 6.8x sales. That is far below its own 5-year average P/E of 107.8x and 5-year average P/S of 12.6x, though those averages came with much richer growth expectations. Given 13% revenue growth, a 20.1% net margin, 16.6% ROIC, and a ~4.2% TTM FCF yield, the stock is reasonably valued and modestly cheap against its own history, not expensive.

The market is paying roughly 33.5x forward earnings for a company guiding to 11-13% revenue growth and 23.5-24% operating margins. That is not a broken-growth value setup, but it leaves limited room for execution stumbles. If DXCM delivers 2026 guidance and grows 2027 EPS toward $3.00+, the current price becomes supportable; if Abbott price competition or payer pressure compresses margins, a de-rate to 28-30x forward EPS would imply a $75-80 range.

As of 2026-08-27, RSI was 60.5, so the stock is not overbought. Price was 1.1% above its 20-day SMA, 13.3% above its 50-day SMA (~$78.8), and 27.7% above its 200-day SMA (~$70.0). The trend is clearly bullish, but the stock is extended versus longer averages; the cleanest entry is either a pullback toward the 50-day SMA or a volume breakout above the 52-week high of $92.59.

• Interest rates: high-growth med-tech multiples remain rate-sensitive, though DXCM's multiple is already well below its own historical average.
• Secular CGM adoption: automated insulin delivery and expanding Type 2 non-insulin coverage provide a long growth runway.
• Pricing/reimbursement: payer negotiations and Abbott Libre competition are structural pricing overhangs; T2NIT-style coverage expansion is a positive offset.
• Med-tech sector sentiment: peer guidance shocks, like Insulet's cut, can cause temporary sector-wide selloffs even when DexCom's fundamentals are intact.
• FDA/regulatory environment: selection for the FDA TAP pilot could accelerate next-generation product timelines and reinforce the competitive moat.

• Q3 2026 earnings, expected late October 2026, with confirmation of raised 2026 revenue guidance and margin durability.
• FDA TAP pilot updates and next-generation CGM pipeline milestones into 2027.
• Continued international G7 expansion, including 16% constant-currency growth and further non-insulin Type 2 coverage wins.
• Additional insulin pump/AID partnership wins or expanded pharmacy-channel distribution.

• Aggressive competition from Abbott's Libre franchise and U.S. payer pricing pressure.
• Margin disappointment if price concessions or G7 transition costs offset volume gains.
• Regulatory or reimbursement setbacks, including FDA delays or coverage restrictions.
• Valuation multiple compression if interest rates stay higher for longer or growth decelerates below guidance.

DexCom is a high-quality compounder with strong margins, high ROIC, clean accruals, and a durable secular growth story. But at $89.29, near the 52-week high and already priced for continued strong execution, the risk/reward is balanced rather than compelling. Long-term investors should prefer a pullback toward the 50-day SMA, while current holders have a reasonable fundamental base to stay constructive. This is analysis, not personalized advice.

Calculated by applying a justified forward P/E of 36x to consensus forward EPS of $2.668. The 36x multiple is a quality/growth-adjusted discount to DXCM's 5-year average P/E of 107.8x and a modest premium to the current 33.5x forward multiple, reflecting ~13% revenue growth, ~20% net margin, 16.6% ROIC, and strong FCF conversion while leaving room for competitive and payer risk.